Answers are grounded in this paper and cite their sources.
Urinary tract infections (UTIs) account for over 1.8 million ED visits yearly in the United States, according to advance data from the Centers of Disease Control and Prevention.1 The Infectious Diseases Society of America (IDSA) recommends trimethoprim–sulfamethoxazole as empiric treatment for UTIs unless regional resistance rates exceed 10–20%.2 However, trimethoprim–sulfamethoxazole resistance exceeds 20% in many areas nationwide, including our community.3 In this circumstance, the IDSA recommends a fluoroquinolone as a first-line agent for uncomplicated UTIs.2 Overuse of fluoroquinolones may increase resistance to a class of agents able to treat a broad range of infections. Although studies have evaluated national trimethoprim–sulfamethoxazole resistance trends and have defined risk factors for multidrug-resistant UTIs, no one has attempted to stratify trimethoprim–sulfamethoxazole resistance based on these risk factors.3 We set out to determine the feasibility of stratifying female patients with uncomplicated UTIs for trimethoprim–sulfamethoxazole resistance. We performed a retrospective chart review for all female patients presenting to the ED from February 2004 to January 2005 with the diagnosis of uncomplicated UTI. Our institution is an urban, tertiary care, teaching hospital with 56,000 ED visits per year. Patients were stratified by the presence or absence of risk factors for a multidrug resistant uro-pathogen. Patient isolates were considered at risk for multidrug-resistant uro-pathogens if they had at least one of the following risk factors: age of ≥65 years, indwelling urinary catheter, antibiotic exposure or hospitalization within the past three months, residence in a long-term-care facility, or diabetes mellitus.3 Patients were excluded if they were male, had pyelonephritis, or were pregnant, admitted to the hospital, or transferred to a different facility. We set out to investigate the difference in trimethoprim–sulfamethoxazole resistance between isolates from patients with and without risk factors and to determine whether trimethoprim–sulfamethoxazole resistance was <20% in those patients without risk factors for multidrug-resistant uropathogens. No a priori level of significance was defined. The study was approved by our institutional review board and did not require informed consent for the retrospective analysis.
No takes yet. Share an insight, caveat, or question.
Mentler et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: